ETS1 and melanoma: Beyond these melanoma-related models, Ets1-deficient OT-I cells improved therapeutic efficacy against OVA-expressing EL4 lymphoma (E.G7-OVA) and Lewis lung carcinoma (LLC-OVA) tumours (Extended Data Fig. 5d), which was associated with enhanced intratumoral OT-I and Tex cell accumulation (Extended Data Fig. 5e–h).